Braveheart, Attovia join next wave of biotech IPOs

The heart drug developer and immune disease specialist aim to capitalize on momentum that’s already yielded several big-ticket IPOs this year.

By Gwendolyn Wu • July 15, 2026

J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

By Ben Fidler • July 15, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Judge orders Apple Tree partner to forfeit oversight of venture fund

The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s portfolio companies.

By Gwendolyn Wu • Updated July 14, 2026

Draig bags another $65M to speed testing of brain drugs

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder. 

By Delilah Alvarado • July 14, 2026

Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.

By Jacob Bell • July 14, 2026

Q32 bounces back to claim study success for alopecia drug

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

By Jonathan Gardner • July 13, 2026

Agenus surges on study pivot; Apnimed lines up an IPO

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

By Ben Fidler • July 13, 2026

Biotech startup funding gap widens despite rebound in VC investment

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

By Gwendolyn Wu • July 13, 2026

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.

By BioPharma Dive staff • July 10, 2026

Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal

An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.

By Ben Fidler • July 8, 2026

Oberland pours up to $400M into MeiraGTx eye gene therapies

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J. 

By Delilah Alvarado • July 7, 2026

Kailera says obesity pill succeeds in late-stage trial in China

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

By Jonathan Gardner • July 7, 2026

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

By Ben Fidler • July 7, 2026

Vera Therapeutics wins FDA nod for closely watched kidney disease drug

The clearance marks another step forward in treatment for IgA nephropathy and sets up a commercial battle with Otsuka, which brought a similar medication to market last year. 

By Delilah Alvarado • July 7, 2026

Gene editing developer Scribe plots an IPO

The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.

By Gwendolyn Wu • July 6, 2026

Novartis to acquire ADC developer in a deal worth up to $1.5B

The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.

By Delilah Alvarado • July 6, 2026

Cancer, immune drugmakers dominate VC funding so far in 2026

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.

By Gwendolyn Wu • July 6, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

A PureTech startup banks $180M for a new IPF drug

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.

By Gwendolyn Wu • July 2, 2026

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.

By Kristin Jensen • July 1, 2026

Abivax shares surge as worries subside over immune drug’s cancer risk

According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.

By Jonathan Gardner • July 1, 2026

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.

By BioPharma Dive staff • June 30, 2026

Viridian may have edge over Amgen in eye drug showdown, analysts argue

The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.

By Delilah Alvarado • June 30, 2026

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

Beeline ups its Series A round for immune drug work

The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.

By Gwendolyn Wu • June 30, 2026